Connect with us
Editorial & Advertiser disclosureOur website provides you with information, news, press releases, Opinion and advertorials on various financial products and services. This is not to be considered as financial advice and should be considered only for information purposes. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third party websites, affiliate sales networks, and may link to our advertising partners websites. Though we are tied up with various advertising and affiliate networks, this does not affect our analysis or opinion. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you, or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish sponsored articles or links, you may consider all articles or links hosted on our site as a partner endorsed link.

News

Memory-Enhancing Drugs Market to Make Great Impact in Near Future by 2028

gbafNews28

VALLEY COTTAGE, N.Y. – Memory-enhancing drugs are used for the treatment of diminished or decreased ability of person to memories due to traumatic injury to the central nervous system (CNS) or due to aging. The start of the memory loss or decreased cognition may result into the onset of the Alzheimer’s disease. Due to traumatic injury especially to the brain, brain cells tend to die and in case of aging person, although memory loss is common but it can be treated with memory-enhancing drugs. Although the market presence of regulatory authorities approved drugs for the memory enhancing drugs is limited but significant number of clinical trials are being carried out to study the outcome. Currently available memory enhancing drugs are mainly derived from food such as vitamins, antioxidants, lipids, etc. Some novel memory enhancing drugs are also approved in different parts of the world for the treatment. Use of off-label drugs like Ritalin and Adderall is increasing as memory-enhancing drugs.

Download the sample copy of Report with table of contents and Figures @ https://www.futuremarketinsights.com/reports/sample/rep-gb-8713

Memory-Enhancing Drugs Market: Drivers and Restraints

The increasing prevalence of aging population and subsequently increasing prevalence of age related dementia expected to drive the growth of the memory-enhancing drugs market. The incidence of traumatic injuries are common and injury to CNS is often common resulting in decrease memorizing power of person, this can be treated with memory-enhancing drugs in turn driving the growth of the market. If the early symptoms of dementia or memory loss are not treated effectively then chances of developing Alzheimer’s disease increases hence early diagnosis of loss of cognition expected to drive the growth of the memory-enhancing drugs market. The significant number of the clinical trials going on in memory-enhancing drugs market and with marketing approval in few countries for the treatment of decreased ability to memories expected to fuel the growth of memory-enhancing drugs market. Although extended efforts on behalf of manufacturers are taken but reluctance in the general population to seek treatment in age related forgetfulness is very limited which in turn may hamper the potential market growth of memory-enhancing drugs.

Preview Analysis of Memory-Enhancing Drugs Market: Global Industry Analysis 2013 – 2017 and Opportunity Assessment; 2018 – 2028 – https://www.futuremarketinsights.com/reports/memory-enhancing-drugs-market

Memory-Enhancing Drugs Market: Segmentation

The global memory-enhancing drugs market is segmented based on the by drug class, route of administration, distribution channel and region

By drug class the memory-enhancing drugs market is segmented as:

  • Cholinesterase Inhibitors
  • Smart Drugs and Cognitive Enhancers (Nootropics)
  • Vitamins and Supplements

By route of administration memory-enhancing drugs market is segmented as:

  • Oral
  • Injectable
  • Topical

By distribution channel memory-enhancing drugs market is segmented as:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Drug Stores

Buy this report @ https://www.futuremarketinsights.com/checkout/8713

Memory-Enhancing Drugs Market: Overview

The age related forgetfulness expected to serve as making of initial foothold for revenue generation in memory-enhancing drugs market in developing as well as developed countries. By the drug class, Smart Drugs and Cognitive Enhancers (Nootropics) segment expected to drive the growth of the memory-enhancing drugs market. By route of administration, oral segment expected to be most lucrative attributing to high patient convenience in the memory-enhancing drugs market. By distribution channel, retail pharmacies expected to be largest revenue generating segment due to higher patient footfall in the memory-enhancing drugs market. Manufacturers in the memory-enhancing drugs market are focusing on developing ‘smart drug’ for enhancing memory capacity and to overcome age related forgetfulness.

Memory-Enhancing Drugs Market: Regional Outlook

The global memory-enhancing drugs market is expected to be dominated by the North America due to higher treatment seeking rate in the early symptoms of Alzheimer’s disease as well as age related forgetfulness. Europe is expected to be second most lucrative memory-enhancing drugs market due to high prevalence of aging population. Asia-Pacific is expected to be emerging memory-enhancing drugs market due to increasing awareness about the available treatment options for the age related forgetfulness as well as traumatic injury-induced memory loss. Latin America memory-enhancing drugs market is expected to experience gradual growth due steadily increasing product penetration in the region. Middle East & Africa is expected to be least lucrative memory-enhancing drugs market due to least low treatment seeking rate as well as least product penetration.

Memory-Enhancing Drugs Market: Key Players

The key market players operating in the memory-enhancing drugs market are: Pfizer Inc., Johnson & Johnson, UCB S.A., Takeda Pharmaceutical Company, Shire plc., Sanochemia Pharmazeutika AG, Allergan plc., Novartis AG, Alkem Laboratories Ltd., Paradigm Healthcare, Intas Pharmaceutical Ltd., Taurus Laboratories Pvt. Ltd., and others.

Our advisory services are aimed at helping you with specific, customized insights that are relevant to your specific challenges. Let us know about your challenges and our trusted advisors will connect with you: https://www.futuremarketinsights.com/askus/rep-gb-8713

More from Healthcare, Pharmaceuticals and Medical devices Market Insights –

About Us

Future Market Insights (FMI) is a leading market intelligence and consulting firm. We deliver syndicated research reports, custom research reports and consulting services which are personalized in nature. FMI delivers a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights and an aerial view of the competitive framework and future market trends.

Contact Us
Mr. Abhishek Budholiya
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
F: +1-845-579-5705
T (UK): + 44-(0)-20-7692-8790 
Sales:[email protected]
Press Office[email protected]
Blog: Market Research Blog
Websitehttps://www.futuremarketinsights.com/

News

Concho Resources Inc. Schedules Third-Quarter 2020 Results Conference Call for Thursday, October 29, 2020

gbafNews28

Concho Resources Inc. (NYSE: CXO) will host a conference call on Thursday, October 29, 2020 at 8:00 AM CT (9:00 AM ET) to discuss third-quarter 2020 financial and operating results. The Company plans to announce third-quarter 2020 results on Wednesday, October 28, 2020, after close of trading.

Conference Call Information:

Dial-in: (844) 263-8298 Intl. dial-in: (478) 219-0007 Participant Passcode: 4263756

To access the live webcast, visit the Companys website at www.concho.com. The replay will also be available on Conchos website under the Investors section.

Concho Resources Inc.

Concho Resources (NYSE: CXO) is one of the largest unconventional shale producers in the Permian Basin, with operations focused on safely and efficiently developing oil and natural gas resources. We are working today to deliver a better tomorrow for our shareholders, people and communities. For more information about Concho, visit www.concho.com.

INVESTOR RELATIONS

Megan P. Hays

Vice President of Investor Relations & Public Affairs

432.685.2533

MEDIA

Mary T. Starnes

Manager of Public Affairs & Corporate Responsibility Strategy

432.221.0477

Continue Reading

News

Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

gbafNews28

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its investigational neuromodulator product, DaxibotulinumtoxinA for Injection, today announced new hire grants totaling an aggregate of 23,500 inducement restricted stock awards (RSAs) to five employees. The RSAs vest over four years, with 25% of the underlying shares vesting on each of the four anniversaries of the applicable vesting commencement date, subject to the new employee’s continued service relationship with Revance through the applicable vesting dates.

The Compensation Committee of Revances Board of Directors approved the awards as an inducement material to the new employees employment in accordance with NASDAQ Listing Rule 5635(c)(4).

About Revance Therapeutics, Inc.

Revance Therapeutics, Inc. is a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA for Injection. DaxibotulinumtoxinA for Injection combines a proprietary stabilizing peptide excipient with a highly purified botulinum toxin that does not contain human or animal-based components. Revance has successfully completed a Phase 3 program for DaxibotulinumtoxinA for Injection in glabellar (frown) lines and is pursuing U.S. regulatory approval in 2020. Revance is also evaluating DaxibotulinumtoxinA for Injection in the full upper face, including glabellar lines, forehead lines and crows feet, as well as in three therapeutic indications – cervical dystonia, adult upper limb spasticity and plantar fasciitis. To accompany DaxibotulinumtoxinA for Injection, Revance owns a unique portfolio of premium products and services for U.S. aesthetics practices, including the exclusive U.S. distribution rights to the RHA Collection of dermal fillers, the first and only range of FDA-approved fillers for correction of dynamic facial wrinkles and folds, and the HintMD fintech platform, which includes integrated smart payment, subscription and loyalty digital services. Revance has also partnered with Mylan N.V. to develop a biosimilar to BOTOX, which would compete in the existing short-acting neuromodulator marketplace. Revance is dedicated to making a difference by transforming patient experiences. For more information or to join our team visit us at www.revance.com.

Revance Therapeutics and the Revance logo are registered trademarks of Revance Therapeutics, Inc. RHA resilient hyaluronic acid and RHA are trademarks of TEOXANE SA. BOTOX is a registered trademark of Allergan, Inc.

Investors

Revance Therapeutics, Inc.:

Jeanie Herbert, 714-325-3584

[email protected]

or

Gilmartin Group, LLC.:

Laurence Watts, 619-916-7620

[email protected]

Media

Revance Therapeutics, Inc.:

Sara Fahy, 949-887-4476

[email protected]

or

General Media:

Y&R:

Jenifer Slaw, 347-971-0906

[email protected]

or

Trade Media:

Nadine Tosk, 504-453-8344

[email protected]

Continue Reading

News

Illumina to Webcast Upcoming Investor Conference Presentation

gbafNews28

Illumina, Inc. (NASDAQ:ILMN) today announced that its executives will be speaking at the following investor conference and invited investors to participate via webcast.

Cowens Liquid Biopsy Summit Thursday, September 24, 2020 at 9:30am Pacific Time

The live webcasts can be accessed in the Investor Info section of Illumina’s web site under the “company” tab at www.illumina.com. A replay of the presentations will be posted on Illuminas website after the event and will be available for at least 30 days following.

About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. To learn more, visit www.illumina.com and connect with us on Twitter, Facebook, LinkedIn, Instagram and YouTube.

Investors:

Jacquie Ross, CFA

+1.858.882.2172

[email protected]

Media:

Dr. Karen Birmingham

+44.7500.105665

[email protected]

Continue Reading
gbafNews28 gbafNews28
News1 hour ago

Marchex Announces Increase in Purchase Price to $2.15 Per Share in the Joint Tender Offer with Edenbrook Capital for Up to 10 million Shares of Marchex’s Class B Common Stock

Marchex (NASDAQ: MCHX), a leading conversational analytics company that connects the voice of the customer to your business, announced today...

gbafNews28 gbafNews28
News1 hour ago

Illumina to Webcast Upcoming Investor Conference Presentation

Illumina, Inc. (NASDAQ:ILMN) today announced that its executives will be speaking at the following investor conference and invited investors to...

gbafNews28 gbafNews28
News1 hour ago

Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its investigational neuromodulator product,...

gbafNews28 gbafNews28
News1 hour ago

Concho Resources Inc. Schedules Third-Quarter 2020 Results Conference Call for Thursday, October 29, 2020

Concho Resources Inc. (NYSE: CXO) will host a conference call on Thursday, October 29, 2020 at 8:00 AM CT (9:00...

gbafNews28 gbafNews28
News1 hour ago

Aspen Technology Receives Staff Determination from Nasdaq

Aspen Technology, Inc. (NASDAQ:AZPN), a global leader in asset optimization software, today announced that it received a notice from Nasdaq...

gbafNews28 gbafNews28
News1 hour ago

Calcium Hydroxide Market 2020 – 2024: Post-Pandemic Industry Planning Structure | Technavio

The calcium hydroxide market is expected to grow by 23.09 million MT during 2020-2024, according to Technavio. The report offers...

gbafNews28 gbafNews28
News1 hour ago

L Squared Closes Third Fund at Hard Cap

In just six years from its founding, L Squared Capital Partners (L Squared or the Firm) has exceeded $1 billion...

gbafNews28 gbafNews28
News1 hour ago

Invacare Corporation to Participate in the Lytham Partners Virtual Investor Growth Conference

Matt Monaghan, chairman, president and chief executive officer of Invacare Corporation (NYSE:IVC), will present at the Lytham Partners Virtual Investor...

gbafNews28 gbafNews28
News1 hour ago

Hamilton ETFs Announces September 2020 Distributions

Hamilton Capital Partners Inc. (Hamilton ETFs) is pleased to announce the cash distributions for its suite of financial services ETFs,...

gbafNews28 gbafNews28
News1 hour ago

Fond Rated #1 Employee Recognition Software by G2 in 4th Consecutive Quarterly Report

Fond, the leading rewards and recognition company, today announced it was named the #1 customer-ranked vendor in G2s Fall 2020...